Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings

Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings

Abstract Patients with breast cancer frequently experience financial hardship, often due to the high costs of anti-cancer drugs. We sought to develop alternative trastuzumab dosing strategies, compare their pharmacokinetic effectiveness to standard dosing, and assess the expected financial implicati...

Full description

Bibliographic Details
Main Authors: Po-Hung Hsieh, Alec J. Kacew, Marie Dreyer, Anthony V. Serritella, Randall W. Knoebel, Garth W. Strohbehn, Mark J. Ratain
Format: Article
Language:English
Published: Nature Portfolio 2022-03-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00393-2

Internet

https://doi.org/10.1038/s41523-022-00393-2

Similar Items